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Abstract
Background:  We  aimed  to  investigate  the  effects  of  metoclopramide  and  ondansetrone  on
mivacurium neuromuscular  blockade.
Methods:  Seventy  ﬁve,  ASA  I-II  patients,  aged  18-65  and  scheduled  for  elective  surgery  requiring
tracheal intubation  were  included  in  the  study.  The  patients  received  metoclopramide  10  mg,
ondansetrone  4  mg  or  normal  saline  5  mL;  group  M,  group  O,  group  NS  (n  =  25),  respectively.
Before anesthesia  study  drugs  were  administered  in  a  volume  of  5  mL.  The  level  of  plasma
cholinesterase  were  obtained  before  and  5  minutes  after  the  administration  of  study  drugs  and
5  minutes  after  the  administration  of  mivacurium.  Onset  time,  T25,  T75,  T25-75,  T90  levels
were  compared  with  each  other  and  differences  between  each  patients  were  investigated.
After recording  T90,  the  study  was  terminated  and  surgery  was  started.
Results: Onset  time  was  signiﬁcantly  shorter  in  group  M,  than  the  other  two  groups.  Onset  time
in group  O  was  signiﬁcantly  shorter  than  in  group  NS.  In  Group  M  T25,  T75,  T90  and  recovery
indices  were  signiﬁcantly  greater  than  in  Group  NS  (p  <  0.001).  In  Group  O  T25,  T75  were  greater
than  Group  NS  (p  <  0.01  and  p  <  0.05,  respectively).  In  Group  M  T75,  T90  and  emergence  indices
were  signiﬁcantly  higher  than  Group  O  (p  <  0.001,  p  <  0.01,  p  <  0.001,  respectively).  In  Groups
M  and  O,  plasma  cholinesterase  levels  decreased  signiﬁcantly  (p  <  0.001)  after  administration
of study  drugs  and  mivacurium.  Plasma  cholinesterase  also  was  reduced  in  Group  NS  5  minutes
after  the  administration  of  mivacurium  (p  <  0.001).
Conclusion:  Ondansetrone  is  believed  to  be  more  reliable  agent  than  metoclopramide  when
used with  mivacurium.
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ntroduction
ivacurium  chloride  is  a  short  acting  non-depolarizing  neu-
omuscular blocking  agent  rapidly  hydrolised  by  plasma
holinesterase (pCHE).  Drugs  which  inhibit  pCHE  prolong
ivacurium neuromuscular  block.1,2 Delayed  recovery  from
euromuscular block  may  compromise  respiratory  effort  and
irway integrity  during  emergence  from  anesthesia.  Meto-
lopramide, which  hastens  gastric  emptying  and  decreases
astroesophageal reﬂux,  is  commonly  used  for  prevention
f nausea  and  vomiting  in  the  early  postoperative  period.3--6
etoclopramide  inhibits  Pche,7 and  giving  it  before  mivac-
rium can  prolong  recovery  time  by  30%,  probably  via
ncreased bioavailability  caused  by  decreased  plasma  clear-
nce of  mivacurium.8,9 Ondansetrone,  a  serotonin  type-3
eceptor antagonist,  is  also  used  to  prevent  nausea  and
omiting.10 The  serotonin  type-3  receptor  is  found  in  both
eripheral and  central  nervous  systems.  Ondansetrone  may
lso  affect  neuromuscular  blockade  by  possible  inhibiting
f Ach  releasing  to  neuromuscular  junction.11--14 In  this
lacebo controlled,  prospective,  randomised  and  double
lind study,  we  aimed  to  investigate  the  effects  of  meto-
lopramide and  ondansetrone  on  mivacurium  neuromuscular
lockade.
aterials and methods
fter  Hospital  Ethics  Committee  approval  and  receipt  of
ritten informed  consent,  seventy  ﬁve  ASA  I-II  status
atients, aged  18-65  and  scheduled  for  elective  surgery
equiring tracheal  intubation  were  included  in  the  study.
atients with  neuromuscular,  liver  and  kidney  diseases,  or
nder medication  known  to  affect  neuromuscular  trans-
ission, with  history  of  difﬁcult  intubation,  malnutrition,
lcohol abuse,  ﬂuid  electrolyte  disturbances,  or  BMI  >  35
ere rejected.  The  patients  were  randomly  assigned
ccording to  computer-generated  random  number  sequence
nto one  of  three  groups  to  receive  metoclopramide,
ndansetrone  or  normal  saline;  group  M  (n  =  25),  group  O
n =  25)  and  group  NS  (n  =  25),  respectively.
In the  operating  room  monitoring  of  DII derivated  ECG,
ulse oximetry  and  non-invasive  arterial  pressure  was  per-
ormed by  Datex-Ohmeda  CardiocapTM/5  (GE,  Finland).  A
eripheric intravenous  line  was  inserted  with  20  gauge
atheter and  0.9  NaCl  infusion  was  started.
Metoclopramide  10  mg,  ondansetrone  4  mg  or  normal
aline were  administered  in  a  volume  of  5  mL,  5  minutes
efore anesthesia  induction.  The  study  drugs  were  pre-
ared by  another  physician  so  all  drugs  were  administered
lindly. Blood  samples  were  obtained  to  measure  the  level
f plasma  cholinesterase  activity,  before  and  5  minutes  after
he administration  of  study  drugs  and  5  minutes  after  the
dministration of  mivacurium.  During  two  hours,  these  sam-
les  were  sent  to  be  centrifuged  in  gel  contained  tubes
t 5,000  rpm  for  ﬁve  minutes.  One  ml  of  obtained  serum
ere inserted  to  the  eppendorf.  Those  samples  were  labeled
s 1,  2,  3  in  order.  They  were  kept  in  ----20 ◦C  in  bio-
hemistry laboratory.  Plasma  cholinesterase  levels  were
easured colorimetrically  with  Vitros  250  Chemistry  System
Ortho-Clinical Diagnostics,  a  Johnson  Johnson  Company).
p
n
(M.  Tercan  et  al.
lasma  cholinesterase  reference  level  was  considered  as  4-
2 U.mL--1.
Anesthesia  was  induced  with  2  g.kg--1 fentanyl  and
.5 mg.kg--1 propofol  and  patient  was  ventilated  manually  by
ask with  %100  oxygen  until  the  intubation.  During  this  time
sing TOF-Watch® SX  (Organon,  Ireland)  and  ulnar  nerve  of
he non-cannulated  arm  was  stimulated  with  supramaximal
50 mA)  train  of  four  stimulation  to  1  Hz  mode  to  obtain  a
100 control  level  (EMAX).
After  obtaining  a  neuromuscular  block  control  level,
.2 mg.kg--1 mivacurium  was  administered  and  the  patient
as intubated.  Anesthesia  was  maintained  by  MAC  1  sevoﬂu-
ane in  an  equal  parts  O2/N2O  mixture  during  operation  and
atient was  ventilated  to  maintain  normocapnia.  Forearm
kin temperature  was  kept  greater  than  32 ◦C.
The time  from  mivacurium  injection  up  to  performing
00% neuromusculary  blockade  was  recorded  as  onset  time.
or assessment  of  neuromuscular  transmission,  TOF  impulse
ith 50  mA  current  was  used  at  5  minutes  intervals  in  ﬁrst
0 minutes  and  once  every  minute  after  10  minutes.  T25,  T75,
25-75,  T90 were  recorded  during  the  study.  Onset  time,  T25,
75, T25-75, T90 levels  were  compared  with  each  other  and
ifferences between  each  patients  were  investigated.  After
ecording  T90, the  study  was  terminated  and  surgery  was
tarted.
At 1st,  3rd, 5th, 10th, 20th and  30th minutes  after  intuba-
ion, mean  arterial  pressure  (MAP),  heart  rate  (HR),  ETCO2,
PO2 were  recorded.  0.5  g.kg--1 IV  fentanyl  and  10  mg  IV
fedrin were  planned  to  be  administered  at  the  time  of  20%
ncrease or  decrease  of  MAP  respectively.
The  data  were  statistically  analyzed  using  SPSS  version
3.0 (SPSS  Inc.,  Chicago,  IL).  The  Kruskal-Wallis  test  was
sed to  assess  differences  among  the  three  groups  with
espect to  non-parametric  variables.  If  this  revealed  sig-
iﬁcant differences,  the  Mann-Whitney  U  test  was  used  to
nalyze differences  between  the  groups  in  pairs.  Nominal
on-parametric data  were  analyzed  using  the  Chi-square
est and  Fisher’s  exact  test.  Data  were  presented  as
ean ±  SD,  median  (range),  and  number  of  patients  (per-
entage) per  category.  P  values  <  0.05  were  considered  to
ndicate statistical  signiﬁcance.
esults
he  three  study  groups  did  not  differ  signiﬁcantly  in
ender, ASA,  age,  weight,  height  and  BMI  (p  >  0.05)
Table 1).
There were  no  differences  in  hemodynamic  parameters
etween groups.  Onset  time  was  signiﬁcantly  shorter  in
roup M  than  the  other  two  groups.  Onset  time  in  group
 was  signiﬁcantly  shorter  than  in  group  NS.  There  was  no
igniﬁcant difference  in  EMAX  values  (p  >  0.05)  (Table  2).
In Group  M  T25,  T75, T90 and  recovery  indices  were  sig-
iﬁcantly greater  than  in  Group  NS  (p  <  0.001).  In  Group  O
25, T75 were  greater  than  Group  NS  (p  <  0.01  and  p  <  0.05,
espectively). In  Group  M  T75,  T90 and  emergence  indices
ere signiﬁcantly  higher  than  Group  O  (p  <  0.001,  p  < 0.01, < 0.001  respectively)  (Table  3).
Although  plasma  cholinesterase  levels  were  all  in  the
ormal range,  there  were  signiﬁcant  differences  in  groups
Table 4).  In  Groups  M  and  O,  plasma  cholinesterase
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Table  1  Demographic  data  (number,  mean  ±  standard  deviation  or  number).
Group  M  Group  O  Group  NS
n  =  25  n  =  25  n  =  25
Gender  (M/F)  4/21  5/20  4/21
ASA (I/II)  18/7  20/5  22/3
Age (year) 44.24  ±  10.38  33.52  ±  10.57  41.32  ±  12.24
Weight  (kg) 66.16  ±  9.46 68.08  ±  9.61 65.48  ±  8.52
Height  (cm) 163.84  ±  5.41 166.36  ±  7.33 162.92  ±  5.61
BMI  24.60  ±  2.96 24.50  ±  2.00 24.60  ±  2.36
ASA, American Society of Anesthesiologists; BMI, Body mass index; F, female; M, male; M, metoclopramide; NS, normal saline; O,
ondansetrone.
Table  2  MAX  and  onset  time  (mean  ±  standard  deviation).
EMAX  Onset  time  (sec)
Group  M  99.6  ±  0.48  138.8  ±  5.82a
b
p
d
s
a
t
d
A
o
s
a
l
d
aGroup  O 99.4  ±  0.50  162.0  ±  9.89
Group  SF  99.3  ±  0.47  168.8  ±  7.67
levels  decreased  signiﬁcantly  (p  <  0.001)  after  administra-
tion of  study  drugs  and  mivacurium.  In  Group  NS,  plasma
cholinesterase level  was  found  to  reduce  5  minutes  after  the
administration of  mivacurium  (p  <  0.001).
DiscussionMetoclopramide  and  ondansetrone  are  commonly  given  to
prevent nausea  and  vomiting  but  their  possible  interactions
with mivacurium  are  not  fully  understood.  Metoclopramide
m
b
d
a
Table  3  T25,  T75,  T90 and  recovery  indices  (minute)  (mean  ±  stan
T25 T75
Group  M  20.92  ±  1.70a 27.92  ±  1.75a,
Group  O  19.80  ±  2.12d 25.04  ±  2.38e
Group NS  17.56  ±  2.45  23.12  ±  2.83  
M, metoclopramide; NS, normal saline; O, ondansetrone.
a p < 0.001; comparing with Group NS.
b p < 0.001; comparing with Group O.
c p < 0.01; comparing with Group O.
d p < 0.01; comparing with Group NS.
e p < 0.05; comparing with Group NS.
Table  4  Plasma  cholinesterase  levels  (med  ±  standar  deviation).
PC1  
Group  M  6.502  ±  0.922  
Group  O  6.124  ±  1.418  
Group  NS  5.895  ±  1.204  
M, metoclopramide; NS, normal saline; O, ondansetrone; PC1, pla
cholinesterase level 5 min after administration of study drug; PC3, plasm
a p < 0.001 evaluation in group.rolongs  the  action  of  succinylcholine,  suggesting  possible
epression of  pCHE  activity,15--17 and  indeed,  it  has  been
hown to  prolong  the  effect  of  mivacurium.8 The  5-HT3
ntagonist  ondansetrone  may  cause  increased  sensitivity  to
he competitive  neuromuscular  blockade  induced  by  non-
epolarising muscle  relaxants  by  reducing  the  release  of
ch.14
We  found  that  metoclopramide  reduced  the  onset  time
f mivacurium  signiﬁcantly  compared  to  ondansetrone  and
aline; ondansetrone  reduced  onset  time  signiﬁcantly  but  to
 lesser  extent.  Metoclopramide  also  reduced  neuromuscu-
ar transmission  more  than  ondansetrone,  but  there  was  no
ifference between  the  two  drugs  in  their  effects  on  pCHE
fter giving  mivacurium.
Motamed et  al.16 studied  the  effect  of  10  and  20  mgetoclopramide on  mivacurium-induced  neuromuscular
lockade. Ten  or  20  mg  metoclopramide  before  an  intubating
ose of  mivacurium  hastened  the  onset  of  maximum  block-
de by  30%  and  prolonged  recovery  by  at  least  50%.  Time
dard  deviation).
T90  Recovery  index
b 33.40  ±  1.77a,c 7.00  ±  0.70a,b
30.44  ±  2.88  5.48  ±  0.87
29.72  ±  3.03  5.24  ±  0.87
PC2  PC3
5.674  ±  0.817a 5.033  ±  0.790a
5.634  ±  1.387a 4.884  ±  1.203a
5.894  ±  1.204  4.998  ±  1.190a
sma cholinesterase level in ﬁrst blood sample; PC2, plasma
a cholinesterase level 5 min after administration of mivacurium.
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18  
o  25%  recovery  was  signiﬁcantly  greater  in  both  metoclo-
ramide groups  compared  to  saline.  A  slight  but  signiﬁcant
eduction in  cholinesterase  activity  was  detected  2  minutes
fter the  administration  of  20  mg  metoclopramide.  In  our
tudy only  10  mg  metoclopramide  decreased  pCHE  activity
igniﬁcantly.
El Ayass  and  Hendrickx  found  a  reduction  of  mivac-
rium infusion  rate  and  a  delay  in  neuromuscular  recovery
fter metoclopramide  10  or  20  mg  in  their  randomised  dou-
le blind  placebo-controlled  study  of  45  patients.18 There
as no  signiﬁcant  change  in  the  onset  time  compared  to
aline, probably  due  to  an  inadequate  number  of  patients.
lasma cholinesterase  level  decreased  in  both  metoclo-
ramide groups.  The  recovery  indices  were  greater  with
etoclopramide compared  to  saline.  While  there  were  sig-
iﬁcant increases  in  the  time  to  recovery  at  25%,  50%,
5% and  90%  with  20  mg,  there  was  only  75%  and  90%
ncrease in  the  time  of  recovery  with  10  mg,  compared
o saline.  We  had  similar  results  with  this  study;  10  mg
etoclopramide prolonged  the  recovery  time  and  indices
y 25%,  75%  and  90%  and  decreased  pCHE  level  signiﬁcan-
ly.
Skinner et  al.8 investigated  the  inﬂuence  of  15  mg.kg--1
etoclopramide  on  pCHE  and  the  duration  of  action  of
ivacurium in  a  randomised  double-blind  study  of  30
atients. Onset  time  and  recovery  index  were  not  affected,
ut there  was  a  reduction  of  pCHE  activity  at  the  time  of
aximum blockade  with  both  metoclopramide  and  saline.
n increased  time  to  recovery  of  T1 to  25%,  75%  and  90%
as seen  in  the  metoclopramide  group.
Lien  et  al.14 found  that  8  and  16  mg  ondansetron  did  not
ffect the  neuromuscular  blockade  induced  by  atracurium  in
heir study  of  30  patients;  ondansetron  may  thus  be  prefer-
ble as  an  antiemetic  agent  when  used  with  other  muscle
elaxant agents  other  than  mivacurium.  We  found  that  4  mg
ndansetrone did  not  affect  mivacurium-induced  neuromus-
ular blockade.
Mivacurium is  hydrolyzed  by  pCHE,  an  enzyme  whose
ctivity is  known  to  be  affected  by  age,  gender,  ethnic
roups and  by  some  physiologic  and  pathologic  situa-
ions. Lepage  et  al.19 studied  factors  affecting  biological
ariations in  total  pCHE  in  3,372  apparently  healthy  sub-
ects more  than  four  years  old.  They  concluded  that
enetic factors,  hormonal  status,  age  and  some  medica-
ions and,  especially  in  males,  BMI,  affected  pCHE.  In
ur study  we  excluded  patients  who  were  more  than  65
ears old  and  with  BMI  >  35.  In  our  study  it  was  impor-
ant to  show  that  pCHE  activity  was  indeed  in  the  normal
ange, because  low  pCHE  activity  causes  prolongation
f mivacurium  induced  neuromuscular  blockade.20,21 After
iving metoclopramide  and  ondansetrone,  enzyme  levels
ecreased in  different  ratios.  After  mivacurium,  enzyme  lev-
ls  decreased  signiﬁcantly  in  all  groups  but  stayed  within
he normal  range,  with  no  signiﬁcant  difference  between
roups.
Considering that  10  mg  metoclopramide  prolonged
ivacurium-induced  neuromuscular  block,  we  believe  that
euromuscular function  should  be  monitored  during  surgery
n order  to  avoid  the  complications  of  excessive  dosage.
ecause ondansetrone  did  not  prolong  T90 or  recovery
ndices, and  affected  other  parameters  of  neuromuscular
lockade less  than  metoclopramide,  we  believe  that  it  is  a
1M.  Tercan  et  al.
ore  reliable  agent  than  metoclopramide  when  used  with
ivacurium.
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